Analyst Price Target is $54.25
▼ -4.81% Downside Potential
This price target is based on 5 analysts offering 12 month price targets for Morphic in the last 3 months. The average price target is $54.25, with a high forecast of $57.00 and a low forecast of $46.00. The average price target represents a -4.81% upside from the last price of $56.99.
Current Consensus is
Hold
The current consensus among 5 investment analysts is to hold stock in Morphic. This Hold consensus rating has held steady for over two years.
Morphic Holding, Inc., a biopharmaceutical company, discovers and develops oral small-molecule integrin therapeutics for the treatment of autoimmune, cardiovascular, and metabolic diseases, as well as fibrosis and cancer. Its lead product candidate MORF-057, an a4ß7-specific integrin inhibitor affecting inflammation is in Phase 2 clinical trials for the treatment of inflammatory bowel disease. The company's products in pipeline include Next Gen a4ß7 Inhibitors for additional potential GI indications, such as EGIDs, pouchitis, etc.; avß8 for the treatment of Myelofibrosis and solid tumor; and fibronectin integrin for pulmonary hypertensive. In addition, it has a license agreement with Janssen to discover and develop novel integrin therapeutics; collaboration agreement with Schrödinger for integrin targets; and license agreement with Children's Medical Center Corporation to develop and commercialize products worldwide for any therapeutic or diagnostic use in humans and veterinary applications. Morphic Holding, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.
Read More